Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 124

1.

Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations.

Pal SK, Rosenberg JE, Hoffman-Censits JH, Berger R, Quinn DI, Galsky MD, Wolf J, Dittrich C, Keam B, Delord JP, Schellens JHM, Gravis G, Medioni J, Maroto P, Sriuranpong V, Charoentum C, Burris HA, Grünwald V, Petrylak D, Vaishampayan U, Gez E, De Giorgi U, Lee JL, Voortman J, Gupta S, Sharma S, Mortazavi A, Vaughn DJ, Isaacs R, Parker K, Chen X, Yu K, Porter D, Graus Porta D, Bajorin DF.

Cancer Discov. 2018 Jul;8(7):812-821. doi: 10.1158/2159-8290.CD-18-0229. Epub 2018 May 30.

PMID:
29848605
2.

Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study.

Kerns SL, Fung C, Monahan PO, Ardeshir-Rouhani-Fard S, Abu Zaid MI, Williams AM, Stump TE, Sesso HD, Feldman DR, Hamilton RJ, Vaughn DJ, Beard C, Huddart RA, Kim J, Kollmannsberger C, Sahasrabudhe DM, Cook R, Fossa SD, Einhorn LH, Travis LB; Platinum Study Group.

J Clin Oncol. 2018 May 20;36(15):1505-1512. doi: 10.1200/JCO.2017.77.0735. Epub 2018 Apr 4.

PMID:
29617189
3.

Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer.

Vaughn DJ, Bellmunt J, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Li H, Perini RF, Bajorin DF, de Wit R.

J Clin Oncol. 2018 Jun 1;36(16):1579-1587. doi: 10.1200/JCO.2017.76.9562. Epub 2018 Mar 28.

PMID:
29590008
4.

Predicting Cardiovascular Disease Among Testicular Cancer Survivors After Modern Cisplatin-based Chemotherapy: Application of the Framingham Risk Score.

Feldman DR, Ardeshir-Rouhani-Fard S, Monahan P, Sesso HD, Fung C, Williams AM, Hamilton RJ, Vaughn DJ, Beard CJ, Cook R, Zaid MA, Lipshultz SE, Einhorn LH, Oeffinger KC, Travis LB, Fossa SD; Platinum Study Group.

Clin Genitourin Cancer. 2018 Aug;16(4):e761-e769. doi: 10.1016/j.clgc.2018.01.011. Epub 2018 Feb 5.

PMID:
29534941
5.

Clinical and Genetic Risk Factors for Adverse Metabolic Outcomes in North American Testicular Cancer Survivors.

Zaid MA, Gathirua-Mwangi WG, Fung C, Monahan PO, El-Charif O, Williams AM, Feldman DR, Hamilton RJ, Vaughn DJ, Beard CJ, Cook R, Althouse SK, Ardeshir-Rouhani-Fard S, Dinh PC Jr, Sesso HD, Einhorn LH, Fossa SD, Travis LB; Platinum Study Group.

J Natl Compr Canc Netw. 2018 Mar;16(3):257-265. doi: 10.6004/jnccn.2017.7046.

PMID:
29523664
6.

Phase 2 Study of Weekly Paclitaxel Plus Estramustine in Metastatic Hormone-Refractory Prostate Carcinoma: ECOG-ACRIN Cancer Research Group (E1898) Trial.

Wong YN, Manola J, Hudes GR, Roth BJ, Moul JW, Barsevick AM, Scher RM, Volk MJ, Vaughn DJ, Williams SD, Fisch MJ, Cella D, Carducci MA, Wilding G.

Clin Genitourin Cancer. 2018 Apr;16(2):e315-e322. doi: 10.1016/j.clgc.2017.10.001. Epub 2017 Oct 16.

PMID:
29173976
7.

Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer.

Dolan ME, El Charif O, Wheeler HE, Gamazon ER, Ardeshir-Rouhani-Fard S, Monahan P, Feldman DR, Hamilton RJ, Vaughn DJ, Beard CJ, Fung C, Kim J, Fossa SD, Hertz DL, Mushiroda T, Kubo M, Einhorn LH, Cox NJ, Travis LB; Platinum Study Group.

Clin Cancer Res. 2017 Oct 1;23(19):5757-5768. doi: 10.1158/1078-0432.CCR-16-3224. Epub 2017 Jun 13.

8.

Bilateral Lung Transplantation for Bleomycin-Associated Lung Injury.

Narayan V, Deshpande C, Bermudez CA, Golato JM, Lee JC, Diamond J, Vaughn DJ.

Oncologist. 2017 May;22(5):620-622. doi: 10.1634/theoncologist.2016-0437. Epub 2017 Mar 30.

9.

Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy.

Fung C, Sesso HD, Williams AM, Kerns SL, Monahan P, Abu Zaid M, Feldman DR, Hamilton RJ, Vaughn DJ, Beard CJ, Kollmannsberger CK, Cook R, Althouse S, Ardeshir-Rouhani-Fard S, Lipshultz SE, Einhorn LH, Fossa SD, Travis LB; Platinum Study Group.

J Clin Oncol. 2017 Apr 10;35(11):1211-1222. doi: 10.1200/JCO.2016.70.3108. Epub 2017 Feb 27.

10.

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.

Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF; KEYNOTE-045 Investigators.

N Engl J Med. 2017 Mar 16;376(11):1015-1026. doi: 10.1056/NEJMoa1613683. Epub 2017 Feb 17.

11.

Variants in WFS1 and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity.

Wheeler HE, Gamazon ER, Frisina RD, Perez-Cervantes C, El Charif O, Mapes B, Fossa SD, Feldman DR, Hamilton RJ, Vaughn DJ, Beard CJ, Fung C, Kollmannsberger C, Kim J, Mushiroda T, Kubo M, Ardeshir-Rouhani-Fard S, Einhorn LH, Cox NJ, Dolan ME, Travis LB.

Clin Cancer Res. 2017 Jul 1;23(13):3325-3333. doi: 10.1158/1078-0432.CCR-16-2809. Epub 2016 Dec 30.

12.

Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer.

Frisina RD, Wheeler HE, Fossa SD, Kerns SL, Fung C, Sesso HD, Monahan PO, Feldman DR, Hamilton R, Vaughn DJ, Beard CJ, Budnick A, Johnson EM, Ardeshir-Rouhani-Fard S, Einhorn LH, Lipshultz SE, Dolan ME, Travis LB.

J Clin Oncol. 2016 Aug 10;34(23):2712-20. doi: 10.1200/JCO.2016.66.8822. Epub 2016 Jun 27.

13.

Risk-Stratified Initial Salvage Therapy for Relapsed or Refractory Metastatic Germ Cell Tumors.

Narayan V, Gunnarsson O, Hwang WT, Squillante CM, Nathanson KL, Stadtmauer EA, Vaughn DJ.

Clin Genitourin Cancer. 2016 Dec;14(6):524-529. doi: 10.1016/j.clgc.2016.03.015. Epub 2016 Mar 24.

PMID:
27083130
14.

Cyclin-Dependent Kinase 4/6 Inhibition for the Treatment of Unresectable Mature Teratoma: Long-Term Follow-Up of a Phase II Study.

Narayan V, Hwang WT, Lal P, Rosen MA, Gallagher M, O'Dwyer PJ, Vaughn DJ.

Clin Genitourin Cancer. 2016 Dec;14(6):504-510. doi: 10.1016/j.clgc.2016.03.010. Epub 2016 Mar 12.

PMID:
27055371
15.

Cisplatin, Gemcitabine, and Lapatinib as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer.

Narayan V, Mamtani R, Keefe S, Guzzo T, Malkowicz SB, Vaughn DJ.

Cancer Res Treat. 2016 Jul;48(3):1084-91. doi: 10.4143/crt.2015.405. Epub 2015 Dec 2.

16.

Palbociclib (PD0332991)-a Selective and Potent Cyclin-Dependent Kinase Inhibitor: A Review of Pharmacodynamics and Clinical Development.

Clark AS, Karasic TB, DeMichele A, Vaughn DJ, O'Hara M, Perini R, Zhang P, Lal P, Feldman M, Gallagher M, O'Dwyer PJ.

JAMA Oncol. 2016 Feb;2(2):253-60. doi: 10.1001/jamaoncol.2015.4701. Review.

PMID:
26633733
17.

Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes.

Lewis JD, Habel LA, Quesenberry CP, Strom BL, Peng T, Hedderson MM, Ehrlich SF, Mamtani R, Bilker W, Vaughn DJ, Nessel L, Van Den Eeden SK, Ferrara A.

JAMA. 2015 Jul 21;314(3):265-77. doi: 10.1001/jama.2015.7996.

PMID:
26197187
18.

Reply to J. Beyer, T. Tandstad et al, S. Gillessen et al, J. Oldenburg et al, and L.C. Pagliaro et al.

Vaughn DJ.

J Clin Oncol. 2015 Jul 10;33(20):2324-5. doi: 10.1200/JCO.2015.61.4834. Epub 2015 Jun 1. No abstract available.

PMID:
26033814
19.

Targeted therapies in germ cell tumors.

Squillante CM, Vaughn DJ.

Urol Oncol. 2015 Aug;33(8):363-9. doi: 10.1016/j.urolonc.2014.09.008. Epub 2014 Dec 24. Review. No abstract available.

PMID:
25544153
20.

Phase 2 trial of the cyclin-dependent kinase 4/6 inhibitor palbociclib in patients with retinoblastoma protein-expressing germ cell tumors.

Vaughn DJ, Hwang WT, Lal P, Rosen MA, Gallagher M, O'Dwyer PJ.

Cancer. 2015 May 1;121(9):1463-8. doi: 10.1002/cncr.29213. Epub 2014 Dec 18.

21.

PD0332991 (palbociclib) for treatment of pediatric intracranial growing teratoma syndrome.

Schultz KA, Petronio J, Bendel A, Patterson R, Vaughn DJ.

Pediatr Blood Cancer. 2015 Jun;62(6):1072-4. doi: 10.1002/pbc.25338. Epub 2014 Nov 21.

PMID:
25417786
22.

Validation of a coding algorithm to identify bladder cancer and distinguish stage in an electronic medical records database.

Mamtani R, Haynes K, Boursi B, Scott FI, Goldberg DS, Keefe SM, Vaughn DJ, Malkowicz SB, Lewis JD.

Cancer Epidemiol Biomarkers Prev. 2015 Jan;24(1):303-7. doi: 10.1158/1055-9965.EPI-14-0677. Epub 2014 Nov 11.

23.

Primum non nocere: active surveillance for clinical stage I testicular cancer.

Vaughn DJ.

J Clin Oncol. 2015 Jan 1;33(1):9-12. doi: 10.1200/JCO.2014.58.2247. Epub 2014 Oct 20. No abstract available.

PMID:
25332248
24.

Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma.

Rangwala R, Chang YC, Hu J, Algazy KM, Evans TL, Fecher LA, Schuchter LM, Torigian DA, Panosian JT, Troxel AB, Tan KS, Heitjan DF, DeMichele AM, Vaughn DJ, Redlinger M, Alavi A, Kaiser J, Pontiggia L, Davis LE, O'Dwyer PJ, Amaravadi RK.

Autophagy. 2014 Aug;10(8):1391-402. doi: 10.4161/auto.29119. Epub 2014 May 20.

25.

Health behaviors among testicular cancer survivors.

Reilley MJ, Jacobs LA, Vaughn DJ, Palmer SC.

J Community Support Oncol. 2014 Apr;12(4):121-8.

PMID:
24971421
26.

Pathway-based analysis of GWAs data identifies association of sex determination genes with susceptibility to testicular germ cell tumors.

Koster R, Mitra N, D'Andrea K, Vardhanabhuti S, Chung CC, Wang Z, Loren Erickson R, Vaughn DJ, Litchfield K, Rahman N, Greene MH, McGlynn KA, Turnbull C, Chanock SJ, Nathanson KL, Kanetsky PA.

Hum Mol Genet. 2014 Nov 15;23(22):6061-8. doi: 10.1093/hmg/ddu305. Epub 2014 Jun 18.

27.

Principles and reality of proton therapy treatment allocation.

Bekelman JE, Asch DA, Tochner Z, Friedberg J, Vaughn DJ, Rash E, Raksowski K, Hahn SM.

Int J Radiat Oncol Biol Phys. 2014 Jul 1;89(3):499-508. doi: 10.1016/j.ijrobp.2014.03.023. Epub 2014 May 3.

28.

Proteinuria testing among patients with diabetes mellitus is associated with bladder cancer diagnosis: potential for unmeasured confounding in studies of pioglitazone and bladder cancer.

Lewis JD, Habel L, Quesenberry C, Mamtani R, Peng T, Bilker WB, Hedderson M, Nessel L, Vaughn DJ, Strom BL, Ferrara A.

Pharmacoepidemiol Drug Saf. 2014 Jun;23(6):636-45. doi: 10.1002/pds.3619. Epub 2014 Apr 25.

PMID:
24764283
29.

Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics.

Travis LB, Fossa SD, Sesso HD, Frisina RD, Herrmann DN, Beard CJ, Feldman DR, Pagliaro LC, Miller RC, Vaughn DJ, Einhorn LH, Cox NJ, Dolan ME; Platinum Study Group.

J Natl Cancer Inst. 2014 Mar 12;106(5). pii: dju044. doi: 10.1093/jnci/dju044. Review.

30.

Incidence of bladder cancer in patients with type 2 diabetes treated with metformin or sulfonylureas.

Mamtani R, Pfanzelter N, Haynes K, Finkelman BS, Wang X, Keefe SM, Haas NB, Vaughn DJ, Lewis JD.

Diabetes Care. 2014 Jul;37(7):1910-7. doi: 10.2337/dc13-1489. Epub 2014 Feb 4.

31.

An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer.

Stadler WM, Vaughn DJ, Sonpavde G, Vogelzang NJ, Tagawa ST, Petrylak DP, Rosen P, Lin CC, Mahoney J, Modi S, Lee P, Ernstoff MS, Su WC, Spira A, Pilz K, Vinisko R, Schloss C, Fritsch H, Zhao C, Carducci MA.

Cancer. 2014 Apr 1;120(7):976-82. doi: 10.1002/cncr.28519. Epub 2013 Dec 11.

32.

Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.

Grivas PD, Daignault S, Tagawa ST, Nanus DM, Stadler WM, Dreicer R, Kohli M, Petrylak DP, Vaughn DJ, Bylow KA, Wong SG, Sottnik JL, Keller ET, Al-Hawary M, Smith DC, Hussain M.

Cancer. 2014 Mar 1;120(5):692-701. doi: 10.1002/cncr.28477. Epub 2013 Nov 18.

33.

Comparison of address-based sampling and random-digit dialing methods for recruiting young men as controls in a case-control study of testicular cancer susceptibility.

Clagett B, Nathanson KL, Ciosek SL, McDermoth M, Vaughn DJ, Mitra N, Weiss A, Martonik R, Kanetsky PA.

Am J Epidemiol. 2013 Dec 1;178(11):1638-47. doi: 10.1093/aje/kwt164. Epub 2013 Sep 5.

34.

In the clinic. Care of the adult cancer survivor.

Jacobs LA, Vaughn DJ.

Ann Intern Med. 2013 Jun 4;158(11):ITC6-1. doi: 10.7326/0003-4819-158-11-201306040-01006. Review. No abstract available.

PMID:
23732730
35.

A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors.

Feldman DR, Einhorn LH, Quinn DI, Loriot Y, Joffe JK, Vaughn DJ, Fléchon A, Hajdenberg J, Halim AB, Zahir H, Motzer RJ.

Invest New Drugs. 2013 Aug;31(4):1016-22. doi: 10.1007/s10637-013-9934-y. Epub 2013 Feb 17.

PMID:
23417696
36.

Phase II clinical trial of oxaliplatin and bevacizumab in refractory germ cell tumors.

Jain A, Brames MJ, Vaughn DJ, Einhorn LH.

Am J Clin Oncol. 2014 Oct;37(5):450-3. doi: 10.1097/COC.0b013e31827de90d.

PMID:
23388561
37.

Chemotherapy refractory testicular germ cell tumor is associated with a variant in Armadillo Repeat gene deleted in Velco-Cardio-Facial syndrome (ARVCF).

Fung C, Vaughn DJ, Mitra N, Ciosek SL, Vardhanabhuti S, Nathanson KL, Kanetsky PA.

Front Endocrinol (Lausanne). 2012 Dec 13;3:163. doi: 10.3389/fendo.2012.00163. eCollection 2012.

38.

Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials.

Sonpavde G, Pond GR, Fougeray R, Choueiri TK, Qu AQ, Vaughn DJ, Niegisch G, Albers P, James ND, Wong YN, Ko YJ, Sridhar SS, Galsky MD, Petrylak DP, Vaishampayan UN, Khan A, Vogelzang NJ, Beer TM, Stadler WM, O'Donnell PH, Sternberg CN, Rosenberg JE, Bellmunt J.

Eur Urol. 2013 Apr;63(4):717-23. doi: 10.1016/j.eururo.2012.11.042. Epub 2012 Nov 26.

39.

Granulomatosis and testicular germ cell tumors.

Jeurkar N, Mamtani R, Vaughn DJ.

Urology. 2012 Dec;80(6):1303-6. doi: 10.1016/j.urology.2012.08.018. Epub 2012 Oct 24.

PMID:
23102438
40.

ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings.

Sternberg CN, Bellmunt J, Sonpavde G, Siefker-Radtke AO, Stadler WM, Bajorin DF, Dreicer R, George DJ, Milowsky MI, Theodorescu D, Vaughn DJ, Galsky MD, Soloway MS, Quinn DI; International Consultation on Urologic Disease-European Association of Urology Consultation on Bladder Cancer 2012.

Eur Urol. 2013 Jan;63(1):58-66. doi: 10.1016/j.eururo.2012.08.010. Epub 2012 Aug 14. Review.

PMID:
22917984
41.

Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study.

Mamtani R, Haynes K, Bilker WB, Vaughn DJ, Strom BL, Glanz K, Lewis JD.

J Natl Cancer Inst. 2012 Sep 19;104(18):1411-21. Epub 2012 Aug 9.

42.

Bladder cancer patterns of pelvic failure: implications for adjuvant radiation therapy.

Baumann BC, Guzzo TJ, He J, Vaughn DJ, Keefe SM, Vapiwala N, Deville C, Bekelman JE, Tucker K, Hwang WT, Malkowicz SB, Christodouleas JP.

Int J Radiat Oncol Biol Phys. 2013 Feb 1;85(2):363-9. doi: 10.1016/j.ijrobp.2012.03.061. Epub 2012 May 30.

PMID:
22658217
43.

A novel risk stratification to predict local-regional failures in urothelial carcinoma of the bladder after radical cystectomy.

Baumann BC, Guzzo TJ, He J, Keefe SM, Tucker K, Bekelman JE, Hwang WT, Vaughn DJ, Malkowicz SB, Christodouleas JP.

Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):81-8. doi: 10.1016/j.ijrobp.2012.03.007. Epub 2012 Apr 28.

PMID:
22543204
44.

Hypogonadism and infertility in testicular cancer survivors.

Jacobs LA, Vaughn DJ.

J Natl Compr Canc Netw. 2012 Apr;10(4):558-63. Review.

PMID:
22491052
45.

Adult type granulosa cell tumor in adult testis: report of a case and review of the literature.

Song Z, Vaughn DJ, Bing Z.

Rare Tumors. 2011 Oct 21;3(4):e37. doi: 10.4081/rt.2011.e37. Epub 2011 Oct 14.

46.

Third-line chemotherapy and novel agents for metastatic germ cell tumors.

Veenstra CM, Vaughn DJ.

Hematol Oncol Clin North Am. 2011 Jun;25(3):577-91, ix. doi: 10.1016/j.hoc.2011.03.005. Epub 2011 Apr 22. Review.

PMID:
21570610
47.

A second independent locus within DMRT1 is associated with testicular germ cell tumor susceptibility.

Kanetsky PA, Mitra N, Vardhanabhuti S, Vaughn DJ, Li M, Ciosek SL, Letrero R, D'Andrea K, Vaddi M, Doody DR, Weaver J, Chen C, Starr JR, Håkonarson H, Rader DJ, Godwin AK, Reilly MP, Schwartz SM, Nathanson KL.

Hum Mol Genet. 2011 Aug 1;20(15):3109-17. doi: 10.1093/hmg/ddr207. Epub 2011 May 6.

48.

Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.

Lewis JD, Ferrara A, Peng T, Hedderson M, Bilker WB, Quesenberry CP Jr, Vaughn DJ, Nessel L, Selby J, Strom BL.

Diabetes Care. 2011 Apr;34(4):916-22. doi: 10.2337/dc10-1068.

49.

Complications associated with chemotherapy in testicular cancer management.

Fung C, Vaughn DJ.

Nat Rev Urol. 2011 Apr;8(4):213-22. doi: 10.1038/nrurol.2011.26. Epub 2011 Mar 15. Review.

PMID:
21403662
50.

Impact of adjuvant chemotherapy on patients with lymph node metastasis at the time of radical cystectomy.

Guzzo TJ, Resnick MJ, Canter DJ, Balandra A, Bergey MR, Magerfleisch L, Tomaszewski JE, Vaughn DJ, Malkowicz SB.

Can J Urol. 2010 Dec;17(6):5465-71.

PMID:
21172112

Supplemental Content

Loading ...
Support Center